MX338150B - Imidazolonilquinolinas [4, 5-c] como inhibidores de proteina cinasa dependiente de adn (adn-pk). - Google Patents

Imidazolonilquinolinas [4, 5-c] como inhibidores de proteina cinasa dependiente de adn (adn-pk).

Info

Publication number
MX338150B
MX338150B MX2013002259A MX2013002259A MX338150B MX 338150 B MX338150 B MX 338150B MX 2013002259 A MX2013002259 A MX 2013002259A MX 2013002259 A MX2013002259 A MX 2013002259A MX 338150 B MX338150 B MX 338150B
Authority
MX
Mexico
Prior art keywords
compounds
formula
quinolines
imidazo
inhibitors
Prior art date
Application number
MX2013002259A
Other languages
English (en)
Other versions
MX2013002259A (es
Inventor
Werner Mederski
Frank Zenke
Thomas Fuchss
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2013002259A publication Critical patent/MX2013002259A/es
Publication of MX338150B publication Critical patent/MX338150B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos de las fórmulas (I) y (II) (Ver Formulas) en donde R1, R2, R3, R4, R5, R8, X y m presentan el significado en las reivindicaciones, y/o sus sales, tautómeros y estereoisómeros fisiológicamente inocuos, incluyendo sus mezclas en todas las proporciones. Los compuestos de la fórmula (I) se pueden usar para la inhibición de las serina-treonina-prote ína cinasas, así como para la sensibilización de células cancerosas a los agentes anticáncer y/o radiación ionizante. También es objeto de la invención el uso de los compuestos de la fórmula (I) en la prevención, la terapia o el control del curso de cáncer, tumores, metástasis o trastornos de la angiogénesis, en combinación con radioterapia y/o un agente anticáncer. La invención también se refiere a un proceso para la preparación de los compuestos de la fórmula (I) por reacción de los compuestos de las fórmulas (II) eventualmente conversión de una base o un ácido de los compuestos de la fórmula (I) en una de sus sales.
MX2013002259A 2010-08-28 2011-07-26 Imidazolonilquinolinas [4, 5-c] como inhibidores de proteina cinasa dependiente de adn (adn-pk). MX338150B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010035744A DE102010035744A1 (de) 2010-08-28 2010-08-28 Imidazolonylchinoline
PCT/EP2011/003744 WO2012028233A1 (de) 2010-08-28 2011-07-26 Imidazo [4,5-c]chinoline als dna-pk-inhibitoren

Publications (2)

Publication Number Publication Date
MX2013002259A MX2013002259A (es) 2013-05-09
MX338150B true MX338150B (es) 2016-04-05

Family

ID=44509164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002259A MX338150B (es) 2010-08-28 2011-07-26 Imidazolonilquinolinas [4, 5-c] como inhibidores de proteina cinasa dependiente de adn (adn-pk).

Country Status (25)

Country Link
US (3) US9000153B2 (es)
EP (1) EP2609082B1 (es)
JP (1) JP5882329B2 (es)
KR (1) KR101912475B1 (es)
CN (1) CN103068803B (es)
AR (1) AR082728A1 (es)
AU (1) AU2011298013B9 (es)
BR (1) BR112013004613B1 (es)
CA (1) CA2809553C (es)
CY (1) CY1116281T1 (es)
DE (1) DE102010035744A1 (es)
DK (1) DK2609082T3 (es)
EA (1) EA022095B1 (es)
ES (1) ES2536313T3 (es)
HK (1) HK1184154A1 (es)
HR (1) HRP20150489T1 (es)
HU (1) HUE025692T2 (es)
IL (1) IL224903A (es)
MX (1) MX338150B (es)
PL (1) PL2609082T3 (es)
PT (1) PT2609082E (es)
RS (1) RS54038B1 (es)
SG (1) SG187954A1 (es)
SI (1) SI2609082T1 (es)
WO (1) WO2012028233A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61664B1 (sr) 2012-04-24 2021-04-29 Vertex Pharma Inhibitori dna-pk
HUE041544T2 (hu) * 2013-03-12 2019-05-28 Vertex Pharma DNS-PK inhibitorok
PT3424920T (pt) 2013-10-17 2020-07-07 Vertex Pharma Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk
NO2714752T3 (es) 2014-05-08 2018-04-21
RU2743343C2 (ru) * 2015-04-02 2021-02-17 Мерк Патент Гмбх Имидазолонилхинолины и их применение в качестве ингибиторов киназы атм
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
CA3038657A1 (en) 2016-09-27 2018-04-05 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
US20200101080A1 (en) * 2017-03-31 2020-04-02 Bioventures, Llc Inhibitors of dna pk and uses thereof
IL272352B2 (en) * 2017-08-11 2023-10-01 Merck Patent Gmbh A pharmaceutical preparation containing 3-fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1 H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[5,4 -C]quinolin-1-yl]-benzonitrile
WO2019177971A1 (en) * 2018-03-12 2019-09-19 Mavupharma, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
RU2020133020A (ru) * 2018-03-14 2022-04-14 Мерк Патент Гмбх Соединения и их применения для лечения опухолей у субъекта
TWI820146B (zh) 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
CN111909144A (zh) * 2019-05-10 2020-11-10 山东轩竹医药科技有限公司 喹唑啉类dna-pk抑制剂
HRP20231548T1 (hr) 2019-07-10 2024-03-15 Merck Patent Gmbh Farmaceutski pripravak
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
CN114615995A (zh) 2019-11-01 2022-06-10 阿雷斯贸易股份有限公司 PD-1、TGFβ和ATM联合抑制与放疗联合用于癌症治疗
CN115916203A (zh) 2020-06-18 2023-04-04 默克专利股份公司 用于治疗病毒感染的化合物
EP4171651A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atm inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK400992A3 (en) 1990-11-06 1995-08-09 Pfizer Quinazolines derivatives for enhancing antitumor activity
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODY FOR INCREASING IRRADIATION IN CANCER THERAPY
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
EP1590348A1 (en) * 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
CA2536136C (en) * 2003-08-27 2012-10-30 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
SG149828A1 (en) * 2003-10-03 2009-02-27 3M Innovative Properties Co Alkoxy substituted imidazoquinolines
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
CN1830964B (zh) * 2005-03-11 2011-06-15 中国科学院上海药物研究所 4-取代苯氨基-3-硝基喹啉类化合物及其制备方法和用途
AR053358A1 (es) 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007056112A2 (en) * 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
CN101541793A (zh) * 2006-11-20 2009-09-23 诺瓦提斯公司 2-甲基-2-[4-(3-甲基-2-氧代-8-喹啉-3-基-2,3-二氢-咪唑并[4,5-c]喹啉-1-基)-苯基]-丙腈的盐和晶型
US20110130386A1 (en) 2008-04-25 2011-06-02 Mark Frigerio Dna-pk inhibitors
EP2303890A4 (en) 2008-06-19 2012-04-11 Progenics Pharm Inc INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
JP5347628B2 (ja) * 2009-03-26 2013-11-20 富士通株式会社 マイクロ構造体
WO2010139731A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
EP2438063A1 (en) * 2009-06-04 2012-04-11 Novartis AG 1h-imidazo[4,5-c]quinolinone compounds, useful for the treatment of proliferative diseases
EP2448937B1 (en) * 2009-06-30 2014-04-09 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and their use in the treatment of tumours and/or inflammations

Also Published As

Publication number Publication date
PL2609082T3 (pl) 2015-07-31
EP2609082B1 (de) 2015-02-18
US9598408B2 (en) 2017-03-21
MX2013002259A (es) 2013-05-09
PT2609082E (pt) 2015-06-05
EP2609082A1 (de) 2013-07-03
RS54038B1 (en) 2015-10-30
US20130172337A1 (en) 2013-07-04
DK2609082T3 (en) 2015-05-11
ES2536313T3 (es) 2015-05-22
WO2012028233A1 (de) 2012-03-08
AR082728A1 (es) 2012-12-26
BR112013004613B1 (pt) 2021-08-03
EA201300288A1 (ru) 2013-08-30
HUE025692T2 (en) 2016-04-28
SG187954A1 (en) 2013-04-30
CN103068803B (zh) 2016-01-20
US9000153B2 (en) 2015-04-07
EA022095B1 (ru) 2015-10-30
AU2011298013A1 (en) 2013-04-11
AU2011298013B2 (en) 2015-01-29
AU2011298013B9 (en) 2015-08-20
CA2809553C (en) 2019-02-26
CY1116281T1 (el) 2017-02-08
JP5882329B2 (ja) 2016-03-09
US20170166567A1 (en) 2017-06-15
IL224903A (en) 2016-02-29
US20150203491A1 (en) 2015-07-23
DE102010035744A1 (de) 2012-03-01
CN103068803A (zh) 2013-04-24
CA2809553A1 (en) 2012-03-08
KR20130106367A (ko) 2013-09-27
HK1184154A1 (zh) 2014-01-17
JP2013536256A (ja) 2013-09-19
SI2609082T1 (sl) 2015-06-30
KR101912475B1 (ko) 2018-10-26
HRP20150489T1 (hr) 2015-06-05
BR112013004613A2 (pt) 2017-04-04

Similar Documents

Publication Publication Date Title
MX338150B (es) Imidazolonilquinolinas [4, 5-c] como inhibidores de proteina cinasa dependiente de adn (adn-pk).
MX361815B (es) Compuestos pirazolopirimidinicos como inhibidores de cinasas.
EA201300073A1 (ru) Пиразолохинолины
EA201201289A1 (ru) Морфолинилхиназолины
MX2014005838A (es) Morfolinilbenzotriazinas para el uso en la terapia de cancer.
NZ630457A (en) Compounds useful as inhibitors of atr kinase
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
NZ604480A (en) Morpholino pyrimidines and their use in therapy
MD4590B1 (ro) Derivaţi macrociclici pentru tratamentul bolilor proliferative
MX2013013294A (es) Inhibidores de tirosina-cinasas.
MX2012007175A (es) Derivados de imidazopiridina como inhibidores de jak.
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
MX2012014017A (es) Derivados de heteroaril imidazolona como inhibidores de jak.
MX2013010898A (es) Novedoso derivados de la pirimidina.
MY184858A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
TN2015000005A1 (en) Azaindole derivatives which act as pi3k inhibitors
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
GB201302704D0 (en) Therapeutic compounds
MX2014011326A (es) Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer.

Legal Events

Date Code Title Description
FG Grant or registration